Oh Seak Hee, Kim Kyung Mo
Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Korean J Pediatr. 2014 Nov;57(11):465-71. doi: 10.3345/kjp.2014.57.11.465. Epub 2014 Nov 30.
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of unknown etiology, which is believed to be multifactorial. Recently, the incidence of pediatric IBD has steeply increased in Korea since 2000. Poorly controlled disease activity can result in complications such as intestinal fistulae, abscess, and stricture, as well as growth retardation and delayed puberty in children. Because of a lack of confirmative tests, various diagnostic modalities must be used to diagnose IBD. Onset age, location, behavior, and activity are important in selecting treatments. Monogenic IBD must be excluded among infantile and refractory very-early-onset IBD. Early aggressive therapy using biologics has recently been proposed for peripubertal children to prevent growth failure and malnutrition.
炎症性肠病（IBD）是一种病因不明的慢性复发性疾病，被认为是多因素导致的。最近，自2000年以来，韩国儿童IBD的发病率急剧上升。疾病活动控制不佳可导致诸如肠瘘、脓肿和狭窄等并发症，以及儿童生长发育迟缓与青春期延迟。由于缺乏确诊检查，必须使用多种诊断方法来诊断IBD。发病年龄、部位、行为和活动情况在选择治疗方法时很重要。在婴儿期和难治性极早发型IBD中必须排除单基因IBD。最近有人提出，对青春期前后的儿童采用生物制剂进行早期积极治疗，以预防生长发育不良和营养不良。
